Gilead: Remdesivir has shown efficacy, it is also important when patients get it


The US pharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD), which manufactures the antiviral drug remdesivir, said the first studies have shown the effectiveness of the drug, but have not yet been peer-reviewed in international publications. Remdesivir is an unsuccessful drug for Ebola, but one of the best candidates to fight the new coronavirus.

Gilead said in a press release that it was an independent study by the US National Institute on Allergies and Infectious Diseases, and that it would be presented in more detail in the coming days. The effectiveness yourself so we do not know a lot of parallel studies, which examine the dosing remdesivirja, while at Gilead verify whether there is a difference in the effectiveness of healthy sation in a number of doses. In their study, they examined whether the difference in the effectiveness of the five-day or 10-day regimen of taking a healthy contract.

Patients who were enrolled had to have developed pneumonia and lower oxygen saturation. After completion of this study, the results suggest that there was no statistically significant difference in the performance of healthy thought, if the patient is taking a healthy ilo five days or ten days. In this study, the time to clinical improvement in 50 percent of patients and 10 days in the group who had a 5-day regimen healthy sation and 11 days in the group who had a 10-day regimen healthy sation. These data and findings have not yet been published in scientific journals and have not yet been peer-reviewed.

Starting time is important

As they say in Gilead, the time is still important, but not the length of healthy thought, the more the beginning, when it was used first dose. In a parallel analysis, patients in the study who started receiving remdesivir within 10 days of symptom onset had better results compared to those who were healthy or after more than 10 days of symptoms. “Data from different clusters show that 62 to 14 percent of patients who left the hospital, was in that group, which is a healthy ILO began to take the first ten days of onset of symptoms. Those who have obtained the ten day After two weeks, they left the hospital in 49 percent. ” The findings presented show that it is not miraculously healthyer, but it could help if the risk groups healthy ILO began to take real time. Of course, there are problems in the global production and distribution of any medicines that would pose additional barriers.